Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ImmunityBio, Inc. (IBRX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622,000 | $240,000 | $934,000 | $605,000 | $2.2M | $47,000 | $45,000 | $44,000 | $236,000 | $641,000 | $600,000 |
| Research & development | — | $190.1M | $232.4M | $248.1M | $196.0M | $139.5M | $112.0M | $55.7M | $42.0M | $29.2M | $11.4M | $1.6M | $446,000 |
| Operating expenses | — | $358.9M | $362.9M | $351.5M | $331.2M | $221.5M | $158.5M | $98.4M | $99.2M | $124.5M | $239.1M | $6.2M | — |
| Operating income | −$256.0M | −$344.2M | −$362.3M | −$351.3M | −$330.3M | −$220.9M | −$156.3M | −$98.4M | −$99.1M | −$124.5M | −$238.9M | −$5.6M | — |
| EBITDAderived | −$240.5M | −$326.6M | −$343.7M | −$333.0M | −$316.0M | −$208.1M | −$142.2M | −$88.8M | −$93.6M | −$120.9M | −$237.4M | −$5.5M | — |
| Net income | −$351.4M | −$413.6M | −$583.2M | −$416.6M | −$346.8M | −$221.9M | −$157.8M | −$96.2M | −$96.4M | −$120.8M | −$236.9M | −$6.2M | −$2.0M |
| Basic EPSper diluted share | -$0.38 | -$0.59 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | -$0.43 | -$1.22 | -$1.20 | -$1.47 | -$3.31 | -$0.75 | -$2.57 |
| Diluted EPSper diluted share | -$0.38 | -$0.62 | -$1.15 | -$1.04 | -$0.89 | -$0.59 | -$0.43 | -$1.22 | -$1.20 | -$1.47 | -$3.31 | -$0.75 | -$2.57 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | Simon Barry J.Director | SellCommon Stock | 25.0K | $7.88 | $197.0K | 2.80M |
| Jun 4, 2026Form 4 · 10b5-1 | Simon Barry J.Director | SellCommon Stock | 23.0K | $7.18 | $165.4K | 2.83M |
| Feb 24, 2026Form 4 · 10b5-1 | Simon Barry J.Director | SellCommon Stock | 75.0K | $12.01 | $900.8K | 2.85M |
| Feb 23, 2026Form 4 · 10b5-1 | Selecky ChristobelDirector | SellCommon Stock | 25.0K | $10.00 | $250.0K | 0 |
| Feb 23, 2026Form 4 · 10b5-1 | Simon Barry J.Director | SellCommon Stock | 165.0K | $10.25 | $1.69M | 2.93M |